<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37539050</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Distribution and clinical significance of anti-carbamylation protein antibodies in rheumatological diseases among the Chinese Han population.</ArticleTitle><Pagination><StartPage>1197458</StartPage><MedlinePgn>1197458</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1197458</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1197458</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Several studies have demonstrated that anti-carbamylation protein antibodies (Anti-CarPA) are persistent in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSC), primary Sj&#xf6;gren's syndrome (pSS), and interstitial lung disease associated with RA (RA-ILD). However, the relationship between anti-CarPA and other rheumatic diseases (RDs) and non-RA-ILD is not known till now. This study sought to examine the presence of anti-CarPA in Chinese Han patients with RDs and its clinical significance.</AbstractText><AbstractText Label="METHODS">The study included 90 healthy controls (HCs) and 300 patients with RDs, including RA, SLE, polymyositis/dermatomyositis (PM/DM), pSS, SSC, spondyloarthritis (SpA), anti-neutrophil cytoplasmic autoantibodies associated with vasculitis (AAV), undifferentiated connective tissue disease (UCTD), and Behcet's disease (BD). Antibodies against carbamylated human serum albumin were detected using commercial enzyme-linked immunosorbent assay kits. Correlations between clinical and laboratory parameters were analyzed.</AbstractText><AbstractText Label="RESULT">Serum levels of anti-CarPA in RA (34.43 &#xb1; 33.34 ng/ml), SLE (21.12 &#xb1; 22.23 ng/ml), pSS (16.32 &#xb1; 13.54 ng/ml), PM/DM (30.85 &#xb1; 17.34 ng/ml), SSC (23.53 &#xb1; 10.70 ng/ml), and UCTD (28.35 &#xb1; 21.91 ng/ml) were higher than those of anti-CarPA in the HCs (7.30 &#xb1; 5.05 ng/ml). The concentration of serum anti-CarPA was higher in patients with rheumatic disease-related interstitial lung disease (RD-ILD), especially RA-ILD, PM/DM-ILD, and pSS-ILD. Patients with RD-ILD who tested positive for anti-CarPA were more likely to have a more severe radiographic classification (grades II, p = 0.045; grades III, p = 0.003). Binary logistic regression analysis suggested that anti-CarPA had an association with ILD in RA (p = 0.033), PM/DM (p = 0.039), and pSS (p = 0.048). Based on receiver operating characteristics (ROC) analysis, anti-CarPA cutoffs best discriminated ILD in RA (&gt;32.59 ng/ml, p = 0.050), PM/DM (&gt;23.46 ng/ml, p = 0.038), and pSS (&gt;37.08 ng/ml, p = 0.040). Moreover, serum levels of anti-CarPA were correlated with antibodies against transcription intermediary factor 1 complex (anti-TIF1) (R = -0.28, p = 0.044), antibodies against glycyl-transfer ribonucleic acid synthetase (anti-EJ) (R = 0.30, p = 0.031), and antibodies against melanoma differentiation-associated gene 5 (anti-MDA5) (R = 0.35, p = 0.011).</AbstractText><AbstractText Label="CONCLUSION">Serum anti-CarPA could be detected in patients with RA, PM/DM, pSS, SSC, and UCTD among the Chinese Han population. And it may also assist in identifying ILD in patients with RA, PM/DM, and pSS, which emphasized attention to the lung involvement in anti-CarPA-positive patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Dong, Sun, Xu, Xiang, Li, Yang, Zhu and Ma.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Rongrong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yuanyuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Weizhen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Meiqi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qingrui</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Zhenzhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019268">Antibodies, Antineutrophil Cytoplasmic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000092522" MajorTopicYN="N">Clinical Relevance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000095225" MajorTopicYN="N">East Asian People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003882" MajorTopicYN="Y">Dermatomyositis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="Y">Rheumatic Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017563" MajorTopicYN="Y">Lung Diseases, Interstitial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012595" MajorTopicYN="Y">Scleroderma, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019268" MajorTopicYN="N">Antibodies, Antineutrophil Cytoplasmic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chinese patients</Keyword><Keyword MajorTopicYN="N">anti-carbamylation protein antibodies</Keyword><Keyword MajorTopicYN="N">autoantibodies</Keyword><Keyword MajorTopicYN="N">interstitial lung disease</Keyword><Keyword MajorTopicYN="N">rheumatic diseases</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>4</Day><Hour>4</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37539050</ArticleId><ArticleId IdType="pmc">PMC10394697</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1197458</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Verheul MK, B&#xf6;hringer S, Delft MAM, Jones JD, Rigby WFC, Gan RW, et al. . Triple positivity for anti&#x2013;citrullinated protein autoantibodies, rheumatoid factor, and anti&#x2013;carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: implications for very early identification of At-risk individuals. Arthritis Rheumatol (2018) 70:1721&#x2013;31. doi:&#xa0;10.1002/art.40562</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40562</ArticleId><ArticleId IdType="pubmed">29781231</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajeganova S, Humphreys JH, Verheul MK, van Steenbergen HW, van Nies JAB, Hafstr&#xf6;m I, et al. . Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts. Ann Rheum Dis (2016) 75:1924&#x2013;32. doi:&#xa0;10.1136/annrheumdis-2015-208579</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-208579</ArticleId><ArticleId IdType="pubmed">26757747</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphreys JH, Verheul MK, Barton A, MacGregor AJ, Lunt M, Toes RE, et al. . Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk arthritis register. Ann Rheum Dis (2016) 75:1139&#x2013;44. doi:&#xa0;10.1136/annrheumdis-2015-207326</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207326</ArticleId><ArticleId IdType="pmc">PMC4893092</ArticleId><ArticleId IdType="pubmed">26443608</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar R, Piantoni S, Boldini M, Garrafa E, Bazzani C, Fredi M, et al. . Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. Clin Exp Rheumatol (2021) 39:91&#x2013;7. doi:&#xa0;10.55563/clinexprheumatol/g8xqxr</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/g8xqxr</ArticleId><ArticleId IdType="pubmed">32359037</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, H&#xf6;rkk&#xf6; S, Barnard J, et al. . Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med (2007) 13:1176&#x2013;84. doi:&#xa0;10.1038/nm1637</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1637</ArticleId><ArticleId IdType="pubmed">17828273</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakabo S, Hashimoto M, Ito S, Furu M, Ito H, Fujii T, et al. . Carbamylated albumin is one of the target antigens of anti-carbamylated protein antibodies. Rheumatol (Oxford). (2017) 56:1217&#x2013;26. doi:&#xa0;10.1093/rheumatology/kex088</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex088</ArticleId><ArticleId IdType="pmc">PMC5850724</ArticleId><ArticleId IdType="pubmed">28398552</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolov EO, Basnakian AG, Ok E, Shah SV. Carbamylated low-density lipoprotein: nontraditional risk factor for cardiovascular events in patients with chronic kidney disease. J Ren Nutr (2012) 22:134&#x2013;8. doi:&#xa0;10.1053/j.jrn.2011.10.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jrn.2011.10.023</ArticleId><ArticleId IdType="pubmed">22200430</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidiras P, Lechanteur J, Imbault V, Sokolova T, Durez P, Rasschaert J. Human carbamylome description identifies carbamylated a2-macroglobulin and hemopexin as two novel autoantigens in early rheumatoid arthritis. Rheumatol (Oxford). (2022) 61:2826&#x2013;34. doi:&#xa0;10.1093/rheumatology/keab838</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab838</ArticleId><ArticleId IdType="pmc">PMC9258537</ArticleId><ArticleId IdType="pubmed">34788409</ArticleId></ArticleIdList></Reference><Reference><Citation>Verheul MK, Yee A, Seaman A, Janssen GM, van Veelen PA, Drijfhout JW, et al. . Identification of carbamylated alpha 1 anti-trypsin (A1AT) as an antigenic target of anti-CarP antibodies in patients with rheumatoid arthritis. J Autoimmun (2017) 80:77&#x2013;84. doi:&#xa0;10.1016/j.jaut.2017.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2017.02.008</ArticleId><ArticleId IdType="pubmed">28291659</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;rkk&#xf6; S, Savolainen MJ, Kervinen K, Kes&#xe4;niemi YA. Carbamylation-induced alterations in low-density lipoprotein metabolism. Kidney Int (1992) 41:1175&#x2013;81. doi:&#xa0;10.1038/ki.1992.179</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1992.179</ArticleId><ArticleId IdType="pubmed">1319520</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaisson S, Pietrement C, Gillery P. Protein carbamylation: chemistry, pathophysiological involvement, and biomarkers. Adv Clin Chem (2018) 84:1&#x2013;38. doi:&#xa0;10.1016/bs.acc.2017.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.acc.2017.12.001</ArticleId><ArticleId IdType="pubmed">29478512</ArticleId></ArticleIdList></Reference><Reference><Citation>Trouw LA, Rispens T, Toes REM. Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis. Nat Rev Rheumatol (2017) 13:331&#x2013;9. doi:&#xa0;10.1038/nrrheum.2017.15</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2017.15</ArticleId><ArticleId IdType="pubmed">28275265</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GMC, van Veelen PA, et al. . Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA (2011) 108:17372&#x2013;7. doi:&#xa0;10.1073/pnas.1114465108</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1114465108</ArticleId><ArticleId IdType="pmc">PMC3198314</ArticleId><ArticleId IdType="pubmed">21987802</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakabo S, Yoshifuji H, Hashimoto M, Imura Y, Nakashima R, Murakami K, et al. . Anti-carbamylated protein antibodies are detectable in various connective tissue diseases. J Rheumatol (2017) 44:1384&#x2013;8. doi:&#xa0;10.3899/jrheum.161432</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.161432</ArticleId><ArticleId IdType="pubmed">28507178</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidiras P, Spruyt D, Gangji V, Imbault V, Sokolova T, Durez P, et al. . Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases. Scand J Rheumatol (2021) 50:118&#x2013;23. doi:&#xa0;10.1080/03009742.2020.1798500</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03009742.2020.1798500</ArticleId><ArticleId IdType="pubmed">33025839</ArticleId></ArticleIdList></Reference><Reference><Citation>Favoino E, Prete M, Vettori S, Corrado A, Cantatore FP, Valentini G, et al. . Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: an intriguing association. PloS One (2018) 13:e0210023. doi:&#xa0;10.1371/journal.pone.0210023</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0210023</ArticleId><ArticleId IdType="pmc">PMC6312283</ArticleId><ArticleId IdType="pubmed">30596753</ArticleId></ArticleIdList></Reference><Reference><Citation>Riccardi A, Martinroche G, Contin-Bordes C, Avouac J, Gobeaux C, Cauvet A, et al. . Erosive arthritis autoantibodies in systemic sclerosis. Semin Arthritis Rheumatol (2022) 52:151947. doi:&#xa0;10.1016/j.semarthrit.2021.11.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2021.11.013</ArticleId><ArticleId IdType="pubmed">35000789</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergum B, Koro C, Delaleu N, Solheim M, Hellvard A, Binder V, et al. . Antibodies against carbamylated proteins are present in primary sj&#xf6;gren&#x2019;s syndrome and are associated with disease severity. Ann Rheum Dis (2016) 75:1494&#x2013;500. doi:&#xa0;10.1136/annrheumdis-2015-207751</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207751</ArticleId><ArticleId IdType="pmc">PMC4975850</ArticleId><ArticleId IdType="pubmed">26350884</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Jia R, Liu Y, Tang S, Ma X, Shi L, et al. . Antibodies against carbamylated vimentin exist in systemic lupus erythematosus and correlate with disease activity. Lupus (2020) 29:239&#x2013;47. doi:&#xa0;10.1177/0961203319897127</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319897127</ArticleId><ArticleId IdType="pubmed">31930936</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zdemir B, Erden A, Erten &#x15e;, Ye&#x15f;il TH, Al&#x131;&#x15f;&#x131;k M, Kucuksahin O. Can anticarbamylated protein antibodies be used to support the diagnosis of systemic lupus erythematosus? biomark Med (2021) 15:1253&#x2013;60. doi:&#xa0;10.2217/bmm-2021-0037</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm-2021-0037</ArticleId><ArticleId IdType="pubmed">34488432</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, van de Stadt LA, Levarht EWN, Huizinga TWJ, Hamann D, van Schaardenburg D, et al. . Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis (2014) 73:780&#x2013;3. doi:&#xa0;10.1136/annrheumdis-2013-204154</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-204154</ArticleId><ArticleId IdType="pubmed">24336334</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal-Bralo L, Perez-Pampin E, Regueiro C, Montes A, Varela R, Boveda MD, et al. . Anti-carbamylated protein autoantibodies associated with mortality in Spanish rheumatoid arthritis patients. PloS One (2017) 12:e0180144. doi:&#xa0;10.1371/journal.pone.0180144</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0180144</ArticleId><ArticleId IdType="pmc">PMC5495341</ArticleId><ArticleId IdType="pubmed">28672020</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellanos-Moreira R, Rodr&#xed;guez-Garc&#xed;a SC, Gomara MJ, Ruiz-Esquide V, Cuervo A, Casafont-Sol&#xe9; I, et al. . Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease. Ann Rheum Dis (2020) 79:587&#x2013;94. doi:&#xa0;10.1136/annrheumdis-2019-216709</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-216709</ArticleId><ArticleId IdType="pubmed">32156708</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie S, Li S, Chen B, Zhu Q, Xu L, Li F. Serum anti-citrullinated protein antibodies and rheumatoid factor increase the risk of rheumatoid arthritis&#x2013;related interstitial lung disease: a meta-analysis. Clin Rheumatol (2021) 40:4533&#x2013;43. doi:&#xa0;10.1007/s10067-021-05808-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-05808-2</ArticleId><ArticleId IdType="pubmed">34189672</ArticleId></ArticleIdList></Reference><Reference><Citation>Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. . Rheumatoid arthritis classification criteria: an American college of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheumatol (2010) 62:2569&#x2013;81. doi:&#xa0;10.1002/art.27584</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27584</ArticleId><ArticleId IdType="pubmed">20872595</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarc&#xf3;n GS, Gordon C, Merrill JT, Fortin PR, et al. . Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheumatol (2012) 64:2677&#x2013;86. doi:&#xa0;10.1002/art.34473</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med (1975) 292:344&#x2013;7. doi:&#xa0;10.1056/NEJM197502132920706</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM197502132920706</ArticleId><ArticleId IdType="pubmed">1090839</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiboski C, Criswell L, Baer A, Challacombe S, Lanfranchi H, Schi&#xf8;dt M, et al. . American College of rheumatology classification criteria for sj&#xf6;gren&#x2019;s syndrome: a data-driven, expert consensus approach in the SICCA cohort. Arthritis Care Res (2012) 64:475&#x2013;87. doi:&#xa0;10.1002/acr.21591</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.21591</ArticleId><ArticleId IdType="pmc">PMC3349440</ArticleId><ArticleId IdType="pubmed">22563590</ArticleId></ArticleIdList></Reference><Reference><Citation>Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. . The American college of rheumatology 1990 criteria for the classification of churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheumatol (1990) 33:1094&#x2013;100. doi:&#xa0;10.1002/art.1780330806</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780330806</ArticleId><ArticleId IdType="pubmed">2202307</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. . Classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 72:1747&#x2013;55. doi:&#xa0;10.1136/annrheumdis-2013-204424</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-204424</ArticleId><ArticleId IdType="pubmed">24092682</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. . The assessment of SpondyloArthritis international society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis (2009) 68:ii1-ii44. doi:&#xa0;10.1136/ard.2008.104018</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.104018</ArticleId><ArticleId IdType="pubmed">19433414</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosca M, Tani C, Vagnani S, Carli L, Bombardieri S. The diagnosis and classification of undifferentiated connective tissue diseases. J Autoimmun (2014) 48-49:50&#x2013;2. doi:&#xa0;10.1016/j.jaut.2014.01.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2014.01.019</ArticleId><ArticleId IdType="pubmed">24518855</ArticleId></ArticleIdList></Reference><Reference><Citation>International Team for the Revision of the International Criteria for Beh&#xe7;et&#x2019;s Disease (ITR-ICBD) Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, et al. . The international criteria for beh&#xe7;et&#x2019;s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. (2014) 28:338&#x2013;47. doi:&#xa0;10.1111/jdv.12107</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.12107</ArticleId><ArticleId IdType="pubmed">23441863</ArticleId></ArticleIdList></Reference><Reference><Citation>Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, et al. . An official American thoracic Society/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 188:733&#x2013;48. doi:&#xa0;10.1164/rccm.201308-1483ST</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201308-1483ST</ArticleId><ArticleId IdType="pmc">PMC5803655</ArticleId><ArticleId IdType="pubmed">24032382</ArticleId></ArticleIdList></Reference><Reference><Citation>Homma Y, Saiki S, Doi O, Yoneda R, Mikami R, Tamura M. Clinical criteria for definition of idiopathic interstitial pneumonia (IIP). Nihon Kyobu Shikkan Gakkai Zasshi. (1992) 30:1371&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1405118</ArticleId></ArticleIdList></Reference><Reference><Citation>Alessandri C, Bartosiewicz I, Pendolino M, Mancini R, Colasanti T, Pecani A, et al. . Anti-carbamylated protein antibodies in unaffected first-degree relatives of rheumatoid arthritis patients: lack of correlation with anti-cyclic citrullinated protein antibodies and rheumatoid factor. Clin Exp Rheumatol (2015) 33:824&#x2013;30. doi:&#xa0;10.1136/annrheumdis-2015-eular.5009</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-eular.5009</ArticleId><ArticleId IdType="pubmed">26411477</ArticleId></ArticleIdList></Reference><Reference><Citation>Brink M, Hansson M, Mathsson-Alm L, Wijayatunga P, Verheul MK, Trouw LA, et al. . Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis. Arthritis Res Ther (2016) 18:43. doi:&#xa0;10.1186/s13075-016-0940-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-016-0940-2</ArticleId><ArticleId IdType="pmc">PMC4748586</ArticleId><ArticleId IdType="pubmed">26860413</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamacchia C, Courvoisier DS, Jarlborg M, Bas S, Roux-Lombard P, M&#xf6;ller B, et al. . Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA for the severity of rheumatoid arthritis. Rheumatol (Oxford). (2021) 60:4598&#x2013;608. doi:&#xa0;10.1093/rheumatology/keab050</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab050</ArticleId><ArticleId IdType="pubmed">33502443</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;enolt L, Grassi W, Szodoray P. Laboratory biomarkers or imaging in the diagnostics of rheumatoid arthritis? BMC Med (2014) 12:49. doi:&#xa0;10.1186/1741-7015-12-49</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-12-49</ArticleId><ArticleId IdType="pmc">PMC3984686</ArticleId><ArticleId IdType="pubmed">24642071</ArticleId></ArticleIdList></Reference><Reference><Citation>Massaro L, Ceccarelli F, Colasanti T, Pendolino M, Perricone C, Cipriano E, et al. . Anti-carbamylated protein antibodies in systemic lupus erythematosus patients with articular involvement. Lupus (2018) 27:105&#x2013;11. doi:&#xa0;10.1177/0961203317713141</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317713141</ArticleId><ArticleId IdType="pubmed">28592200</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceccarelli F, Perricone C, Colasanti T, Massaro L, Cipriano E, Pendolino M, et al. . Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus. Arthritis Res Ther (2018) 20:126. doi:&#xa0;10.1186/s13075-018-1622-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-018-1622-z</ArticleId><ArticleId IdType="pmc">PMC6001021</ArticleId><ArticleId IdType="pubmed">29898764</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein M, Mann H, Vencovsk&#xfd; J. Arthritis in idiopathic inflammatory myopathies. Curr Rheumatol Rep (2019) 21:70. doi:&#xa0;10.1007/s11926-019-0878-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-019-0878-x</ArticleId><ArticleId IdType="pubmed">31813070</ArticleId></ArticleIdList></Reference><Reference><Citation>Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, Knight JS, et al. . NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med (2013) 5:178ra40. doi:&#xa0;10.1126/scitranslmed.3005580</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3005580</ArticleId><ArticleId IdType="pmc">PMC3727661</ArticleId><ArticleId IdType="pubmed">23536012</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neil LJ, Barrera-Vargas A, Sandoval-Heglund D, Merayo-Chalico J, Aguirre-Aguilar E, Aponte AM, et al. . Neutrophil-mediated carbamylation promotes articular damage in rheumatoid arthritis. Sci Adv (2020) 6:eabd2688. doi:&#xa0;10.1126/sciadv.abd2688</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abd2688</ArticleId><ArticleId IdType="pmc">PMC7608797</ArticleId><ArticleId IdType="pubmed">33115748</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue J, Hu W, Wu S, Wang J, Chi S, Liu X. Development of a risk nomogram model for identifying interstitial lung disease in patients with rheumatoid arthritis. Front Immunol (2022) 13:823669. doi:&#xa0;10.3389/fimmu.2022.823669</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.823669</ArticleId><ArticleId IdType="pmc">PMC9245420</ArticleId><ArticleId IdType="pubmed">35784288</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka S, Higuchi T, Furukawa H, Shimada K, Okamoto A, Hashimoto A, et al. . Serum rheumatoid factor IgA, anti-citrullinated peptide antibodies with secretory components, and anti-carbamylated protein antibodies associate with interstitial lung disease in rheumatoid arthritis. BMC Musculoskelet Disord (2022) 23:46. doi:&#xa0;10.1186/s12891-021-04985-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12891-021-04985-0</ArticleId><ArticleId IdType="pmc">PMC8756729</ArticleId><ArticleId IdType="pubmed">35027028</ArticleId></ArticleIdList></Reference><Reference><Citation>Gono T, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Ikeda K, et al. . Risk prediction modeling based on a combination of initial serum biomarker levels in Polymyositis/Dermatomyositis&#x2013;associated interstitial lung disease. Arthritis Rheumatol (2021) 73:677&#x2013;86. doi:&#xa0;10.1002/art.41566</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41566</ArticleId><ArticleId IdType="pubmed">33118321</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunawardena H. The clinical features of myositis-associated autoantibodies: a review. Clinic Rev Allerg Immunol (2017) 52:45&#x2013;57. doi:&#xa0;10.1007/s12016-015-8513-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-015-8513-8</ArticleId><ArticleId IdType="pubmed">26453338</ArticleId></ArticleIdList></Reference><Reference><Citation>Khawaja AA, Chong DLW, Sahota J, Mikolasch TA, Pericleous C, Ripoll VM, et al. . Identification of a novel HIF-1&#x3b1;-&#x3b1;M&#x3b2;2 integrin-NET axis in fibrotic interstitial lung disease. Front Immunol (2020) 11:2190. doi:&#xa0;10.3389/fimmu.2020.02190</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.02190</ArticleId><ArticleId IdType="pmc">PMC7594517</ArticleId><ArticleId IdType="pubmed">33178179</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Jia X, Zhang Q, Zhang L, Yang J, Hu C, et al. . Neutrophil extracellular traps activate lung fibroblast to induce polymyositis-related interstitial lung diseases via TLR9-miR-7-Smad2 pathway. J Cell Mol Med (2020) 24:1658&#x2013;69. doi:&#xa0;10.1111/jcmm.14858</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.14858</ArticleId><ArticleId IdType="pmc">PMC6991674</ArticleId><ArticleId IdType="pubmed">31821687</ArticleId></ArticleIdList></Reference><Reference><Citation>Seto N, Torres-Ruiz JJ, Carmona-Rivera C, Pinal-Fernandez I, Pak K, Purmalek MM, et al. . Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. JCI Insight (2020) 5:e134189. doi:&#xa0;10.1172/jci.insight.134189</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.134189</ArticleId><ArticleId IdType="pmc">PMC7098779</ArticleId><ArticleId IdType="pubmed">31945019</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Chang X, Zhang J, Liu C, Liu M, Chen W. Clinical and laboratory features of primary sj&#xf6;gren&#x2019;s syndrome complicated with mild to severe thrombocytopenia. Ann Transl Med (2022) 10:300. doi:&#xa0;10.21037/atm-22-162</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm-22-162</ArticleId><ArticleId IdType="pmc">PMC9011250</ArticleId><ArticleId IdType="pubmed">35433982</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>